First-Line Treatment Options for Patients With Transplant-Ineligible NDMM

Video

Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      “If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
      JNJ-5322 Shows Efficacy in Later-Line Multiple Myeloma
      Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
      MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
      The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
      JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
      The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Related Content
      FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

      FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

      Tim Cortese
      June 27th 2025
      Article

      The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Efficacy with etentamig was comparable across prespecified subgroups with relapsed/refractory multiple myeloma, suggesting broad therapeutic benefit.

      Etentamig Displays Durable Responses, Tolerability in R/R Multiple Myeloma

      Roman Fabbricatore
      June 22nd 2025
      Article

      Efficacy with etentamig was comparable across prespecified subgroups with relapsed/refractory multiple myeloma, suggesting broad therapeutic benefit.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

      Data Show Enduring Responses With Talquetamab Combo in R/R Multiple Myeloma

      Gina Mauro
      June 18th 2025
      Article

      Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

      Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

      Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

      Ariana Pelosci
      June 16th 2025
      Article

      The MagnetisMM-6 trial results showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.